WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Gautam Patel Biography and Net Worth

Director of Amneal Pharmaceuticals

Gautam Patel has served as Managing Director of Tarsadia Investments, a private investment firm based in Newport Beach, CA since 2012. In that role, Mr. Patel has led a team of investment professionals to identify, evaluate and execute principal equity investments across sectors including life sciences, financial services and technology. Prior to joining Tarsadia, Mr. Patel served as Managing Director at Lazard from 2008 to 2012, where he led financial and strategic advisory efforts in sectors including transportation and logistics, private equity, specialty pharmaceuticals and medical devices. Prior to that, Mr. Patel served in a variety of roles at Lazard from 1999 to 2008, including multiple restructuring, bankruptcy and corporate reorganization assignments. From 1994 to 1997, Mr. Patel was an Analyst at Donaldson, Lufkin & Jenrette (DLJ), where he worked on M&A as well as high-yield and equity financings. Mr. Patel is currently a Board Member of companies such as Amneal Pharmaceuticals, Adello Biologics, Asana Biosciences, LERETA and AIONX Antimicrobial Technologies, as well as Tarsadia Foundation. Mr. Patel received a B.A. from Claremont McKenna College, a B.S. from Harvey Mudd College, an M.S. from the London School of Economics (LSE) and an MBA from the University of Chicago. Mr. Patel’s extensive experience as an advisor, investor and operator in generics and the pharmaceutical industry broadly will provide the Board with insight regarding business development, strategic planning and operational management.

What is Gautam Patel's net worth?: The estimated net worth of Gautam Patel is at least $297,336.04 as of March 2nd, 2020. Mr. Patel owns 38,218 shares of Amneal Pharmaceuticals stock worth more than $297,336 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Patel may own. Learn More about Gautam Patel's net worth.
How do I contact Gautam Patel?: The corporate mailing address for Mr. Patel and other Amneal Pharmaceuticals executives is 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807, United States. Amneal Pharmaceuticals can also be reached via phone at 908-947-3120 and via email at [email protected]. Learn More on Gautam Patel's contact information.
Has Gautam Patel been buying or selling shares of Amneal Pharmaceuticals?: Gautam Patel has not been actively trading shares of Amneal Pharmaceuticals during the past quarter. Most recently, on Friday, December 17th, Gautam Patel bought 50,000 shares of Amneal Pharmaceuticals stock. The stock was acquired at an average cost of $4.21 per share, with a total value of $210,500.00. Learn More on Gautam Patel's trading history.
Who are Amneal Pharmaceuticals' active insiders?: Amneal Pharmaceuticals' insider roster includes Andrew Boyer (EVP, Chief Commercial Officer – Generics), Chirag Patel (Co-Founder, Co-CEO, President & Director), Gautam Patel (Director), Nikita Shah (EVP), and Joseph Todisco (EVP). Learn More on Amneal Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amneal Pharmaceuticals?: During the last year, insiders at the sold shares 1 times. They sold a total of 43,657 shares worth more than $375,886.77. The most recent insider tranaction occured on November, 15th when SVP Jason B Daly sold 43,657 shares worth more than $375,886.77. Insiders at Amneal Pharmaceuticals own 26.6% of the company. Learn More about insider trades at Amneal Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Gautam Patel Insider Trading History at Amneal Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/17/2021	Buy	50,000	$4.21	$210,500.00
3/2/2020	Buy	32,111	$3.88	$124,590.68	38,218

Gautam Patel Buying and Selling Activity at Amneal Pharmaceuticals

Amneal Pharmaceuticals Company Overview

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Today's Range

Now: $7.78

$7.57

$7.86

50 Day Range

MA: $8.42

$7.69

$9.25

2 Week Range

Now: $7.78

$5.01

$9.48

Volume

1,657,823 shs

Average Volume

1,382,215 shs

Market Capitalization

$2.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12